Abstract
Propranolol, a β-adrenergic blocker agent widely used in a number of cardiovascular disorders, increases plasminogen activator (PA) activity in confluent bovine aortic endothelial cells (BAEC). This effect is time and dose dependent (10-100 μM). Hybridization studies with specific cDNA showed that propranolol was able to induce an increase in urokinase mRNA expression in a dose and time dependent manner. The propranolol effect seems to be specific for urokinase mRNA, because it does not affect a-actin mRNA expression. Cycloheximide, similarly to propranolol, also increases urokinase mRNA, indicating that the gene expression may be regulated by some rapidly turning over protein. When both compounds were used in combination, a superinduction phenomenon was observed.
| Original language | English |
|---|---|
| Pages (from-to) | 977-981 |
| Number of pages | 5 |
| Journal | Biochemical and Biophysical Research Communications |
| Volume | 160 |
| Issue number | 3 |
| DOIs | |
| Publication status | Published - May 15 1989 |
Fingerprint
ASJC Scopus subject areas
- Biochemistry
- Biophysics
- Molecular Biology
Cite this
Increased expression of urokinase mRNA in bovine aortic endothelial cells treated with propranolol. / Peracchia, Francesca; Polentarutti, Nadia; Colotta, Francesco; Mussoni, Luciana.
In: Biochemical and Biophysical Research Communications, Vol. 160, No. 3, 15.05.1989, p. 977-981.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Increased expression of urokinase mRNA in bovine aortic endothelial cells treated with propranolol
AU - Peracchia, Francesca
AU - Polentarutti, Nadia
AU - Colotta, Francesco
AU - Mussoni, Luciana
PY - 1989/5/15
Y1 - 1989/5/15
N2 - Propranolol, a β-adrenergic blocker agent widely used in a number of cardiovascular disorders, increases plasminogen activator (PA) activity in confluent bovine aortic endothelial cells (BAEC). This effect is time and dose dependent (10-100 μM). Hybridization studies with specific cDNA showed that propranolol was able to induce an increase in urokinase mRNA expression in a dose and time dependent manner. The propranolol effect seems to be specific for urokinase mRNA, because it does not affect a-actin mRNA expression. Cycloheximide, similarly to propranolol, also increases urokinase mRNA, indicating that the gene expression may be regulated by some rapidly turning over protein. When both compounds were used in combination, a superinduction phenomenon was observed.
AB - Propranolol, a β-adrenergic blocker agent widely used in a number of cardiovascular disorders, increases plasminogen activator (PA) activity in confluent bovine aortic endothelial cells (BAEC). This effect is time and dose dependent (10-100 μM). Hybridization studies with specific cDNA showed that propranolol was able to induce an increase in urokinase mRNA expression in a dose and time dependent manner. The propranolol effect seems to be specific for urokinase mRNA, because it does not affect a-actin mRNA expression. Cycloheximide, similarly to propranolol, also increases urokinase mRNA, indicating that the gene expression may be regulated by some rapidly turning over protein. When both compounds were used in combination, a superinduction phenomenon was observed.
UR - http://www.scopus.com/inward/record.url?scp=0024349594&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0024349594&partnerID=8YFLogxK
U2 - 10.1016/S0006-291X(89)80096-8
DO - 10.1016/S0006-291X(89)80096-8
M3 - Article
C2 - 2730649
AN - SCOPUS:0024349594
VL - 160
SP - 977
EP - 981
JO - Biochemical and Biophysical Research Communications
JF - Biochemical and Biophysical Research Communications
SN - 0006-291X
IS - 3
ER -